Duru Serap, Yüce Gülbahar, Fırat Hikmet, Şimşek Bengül, Uçar Fatma, Ardıç Sadık, Kurt Emine Bahar
Clinic of Chest Diseases, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
Tuberk Toraks. 2015 Sep;63(3):158-64. doi: 10.5578/tt.9753.
YKL-40 [chitinase-3 like-1 (CHI3L1)] is a glycoprotein, has been implicated in inflammation, endothelial dysfunction, tissue remodelling and it is accepted as a noninvasive prognostic biomarker for inflammation. In this study, we aimed to underline usability of serum YKL-40 as an inflammatory biomarker in patients with obstructive sleep apnea syndrome (OSAS).
Two groups OSAS patients [Group I: Mild-moderate OSAS, n:43; median apnea-hypopnea index: AHI, /hour:18], Group II: Severe OSAS, n: 25; AHI:41.6] and healthy control group [n:25, AHI: 3.6] were included in the study. Serum YKL-40 level was tested in serum samples taken after polysomnography in OSAS patients and control group. In addition, the association of serum YKL-40 level with age, body mass index and polysomnografic parameters were analyzed in the OSAS patient groups.
Median serum YKL-40 level was 20.30 ng/mL (range 8.01-73 ng/mL) in mild-moderate OSAS patients, and 22.58 ng/mL (9.17-99 ng/mL in severe OSAS patients, 18 ng/mL (range 7.36-88 ng/mL) in control group (p< 0.05). Serum YKL-40 level was found to be correlated with AHI in patient with mild-moderate OSAS patients (p< 0.05) and serum YKL-40 level was found to be correlated with age, total hypopnea time (minutes) in severe OSAS patients (p< 0.05). There was no relationship serum YKL-40 level with other studied variables (p> 0.05).
At the end of this study, we found that serum YKL-40 level increase with severity of OSAS. The findings suggest that YKL-40 may be a useful biomarker for inflammation in patients with OSAS.
YKL-40[几丁质酶-3样蛋白1（CHI3L1）]是一种糖蛋白，与炎症、内皮功能障碍、组织重塑有关，并且被认为是一种用于炎症的非侵入性预后生物标志物。在本研究中，我们旨在强调血清YKL-40作为阻塞性睡眠呼吸暂停综合征（OSAS）患者炎症生物标志物的可用性。
本研究纳入两组OSAS患者[第一组：轻度至中度OSAS，n：43；呼吸暂停低通气指数中位数：AHI，次/小时：18]，第二组：重度OSAS，n：25；AHI：41.6]以及健康对照组[n：25，AHI：3.6]。在OSAS患者和对照组进行多导睡眠图检查后采集的血清样本中检测血清YKL-40水平。此外，在OSAS患者组中分析血清YKL-40水平与年龄、体重指数和多导睡眠图参数之间的关联。
轻度至中度OSAS患者血清YKL-40水平中位数为20.30 ng/mL（范围8.01 - 73 ng/mL），重度OSAS患者为22.58 ng/mL（9.17 - 99 ng/mL），对照组为18 ng/mL（范围7.36 - 88 ng/mL）（p < 0.05）。在轻度至中度OSAS患者中发现血清YKL-40水平与AHI相关（p < 0.05），在重度OSAS患者中发现血清YKL-40水平与年龄、总呼吸暂停时间（分钟）相关（p < 0.05）。血清YKL-40水平与其他研究变量之间无相关性（p > 0.05）。
在本研究结束时，我们发现血清YKL-40水平随OSAS严重程度增加而升高。这些发现表明YKL-40可能是OSAS患者炎症的有用生物标志物。
